Aim: Albendazole (ABZ) is a broad-spectrum antiparasitic agent with poor aqueous solubility, which leads to poor/erratic bioavailability and therapeutic failures. Here, we aimed to produce a novel formulation of ABZ nanocrystals (ABZNC) and assess its pharmacokinetic performance in mice. Results/methodology: ABZNC were prepared by high-pressure homogenization and spray-drying processes. Redispersion capacity and solid yield were measured in order to obtain an optimized product. The final particle size was 415.69±7.40 nm and the solid yield was 72.32%. The pharmacokinetic parameters obtained in a mice model for ABZNC were enhanced (p < 0.05) with respect to the control formulation. Conclusion: ABZNC with improved pharmacokinetic behavior were produced by a simple, inexpensive and potentially scalable methodology.
Paredes, A. J., Bruni, S. S., Allemandi, D., Lanusse, C., & Palma, S. D. (2018). Albendazole nanocrystals with improved pharmacokinetic performance in mice. Therapeutic Delivery. https://doi.org/10.4155/tde-2017-0090